Law of the vital few: choosing variables of disease activity in rheumatoid arthritis.

Law of the vital few: choosing variables of disease activity in rheumatoid arthritis. J Rheumatol. 2014 Nov;41(11):2097-8 Authors: Dumitru B, Buch M, Vital EM PMID: 25362705 [PubMed - in process]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research

Related Links:

ConclusionThe management of RA in the older population poses its own challenges but this should not prohibit the thoughtful use of newer agents. Awareness of the therapeutic potential and associated adverse events is necessary for maximizing therapeutic benefits while minimizing adverse effects from conventional DMARDs and biologic therapies.
Source: Age and Ageing - Category: Geriatrics Source Type: research
ConclusionBiologic prescribing was similar between both groups with regard to the dosage administered, but there were differences in the types of biologics prescribed to each group. Rates of significant infection were low overall, however they were more prevalent amongst the older population. More older patients had active disease, and more were prescribed concomitant steroid therapy, which may represent under-dosing of biologic therapy in this older cohort.
Source: Age and Ageing - Category: Geriatrics Source Type: research
ConclusionWe could not identify any significant relationship between RA and dementia.Key Points•Two studies were conducted to identify the relationship between rheumatoid arthritis and dementia using national cohort data.•Neither study showed any association between rheumatoid arthritis and dementia.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
AbstractObjectivesCXC ligand 13 (CXCL13) is known as B cell chemotactic factor (BLC), promoting the migration of B lymphocytes by communicating with its receptor CXCR5, which can be regarded as part of pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). This meta-analysis was to evaluate the circulating CXCL13 levels in SLE and RA.MethodsAll articles were respectively gathered from PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) (by the end of 10 April 2019). According to random effects model, standardized mean difference (SMD) and 95% confidence interval (CI) of CXC...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
ConclusionStudies have shown that IL-6 inhibitors can be effective in the management of NIU. In addition, the levels of IL-6 are elevated in other ocular vascular diseases such as retinal vein occlusion and diabetic macular edema. The roles of IL-6 inhibition may be broadened in the future to include the management of retinal vascular diseases and non-uveitic macular edema.
Source: Journal of Ophthalmic Inflammation and Infection - Category: Opthalmology Source Type: research
ConclusionsDisease burden in patients with PsA or axSpA was comparable to or greater than that in patients with RA on the basis of common patient-reported outcome measures but appeared lower when assessed using RA disease activity measures, suggesting that disease-specific approaches to care are needed to optimize disease management.FundingThis study was sponsored by Corrona, LLC, and financial support was provided by Novartis. The Rapid Service Fee was funded by Novartis.Plain Language SummaryPlain language summary available for this article.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
Conclusion: Rheumatologists highly valued patient-reported RA symptoms and physical function to inform their treatment decisions, even above objective data such as physical findings and test results. These results can guide the selection of validated PRO measures to assess these domains to inform the clinical care of patients with rheumatoid arthritis. PMID: 31517249 [PubMed]
Source: Pain Physician - Category: Anesthesiology Authors: Tags: BMC Rheumatol Source Type: research
Publication date: Available online 12 September 2019Source: Joint Bone SpineAuthor(s): Thomas El Jammal, Mathieu Gerfaud-Valentin, Pascal Sève, Yvan JamillouxAbstractThree Janus kinase (JAK) inhibitors, ruxolitinib, tofacitinib, and baricitinib, are currently approved by the FDA/EMA for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative rectocolitis. The inhibition of JAK/STAT signaling by these small molecules, downstream of several cytokine receptors, results in lower pro-inflammatory gene expression. Given the cytokine profiles observed in rheumatologic diseases, most of the recent therape...
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
AbstractPurposeTo determine if a novel individualized-ultrasound (IUS) method can detect more joints with erosion(s) in rheumatoid arthritis (RA) patients versus existing methods.Materials and methodsThe IUS method selects up to 7 or 14 ultrasonographically most inflamed joints whereas existing methods pre-fix 7 or 14 joints for ultrasonography. Using ultrasonography, the mean total inflammatory score (TIS), mean number of affected joints and mean number of joints with erosion(s) were compared between novel and existing methods among 30 RA patients using the paired Studentt test.ResultsUsing 7-joint approach, comparing IUS...
Source: Japanese Journal of Radiology - Category: Radiology Source Type: research
ConclusionsAnti-TNF therapy slowed down generalized bone loss, in association with clinical improvements, in both diseases. TNF blockade may enhance bone formation and suppress joint destruction. Anti-TNF therapy may act inversely on DKK-1 and SOST. Independent predictors of BMD were SOST and βCTX in RA, whilst CRP in AS.Key Points• One-year anti-TNF therapy halted generalized bone loss in association with clinical improvement in arthritides.• Anti-TNF therapy may inversely act on DKK-1 and SOST.• Independent predictors of BMD were SOST and βCTX in RA, while CRP in AS.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
More News: Arthritis | Rheumatoid Arthritis | Rheumatology